Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk

Clifford J. Bailey

doi:10.1016/S2213-8587(19)30414-0

Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk

Clifford J. Bailey

Research output: Contribution to journal › Letter, comment/opinion or interview › peer-review

Original language	English
Pages (from-to)	97-99
Number of pages	3
Journal	The Lancet Diabetes and Endocrinology
Volume	8
Issue number	2
Early online date	13 Dec 2019
DOIs	https://doi.org/10.1016/S2213-8587(19)30414-0
Publication status	Published - 1 Feb 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S2213-8587(19)30414-0

Cite this

@article{5df81d58032e48dfb560989882fe8353,

title = "Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk",

author = "Bailey, \{Clifford J.\}",

year = "2020",

month = feb,

day = "1",

doi = "10.1016/S2213-8587(19)30414-0",

language = "English",

volume = "8",

pages = "97--99",

journal = "The Lancet Diabetes and Endocrinology",

issn = "2213-8587",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk

AU - Bailey, Clifford J.

PY - 2020/2/1

Y1 - 2020/2/1

UR - https://www.scopus.com/pages/publications/85078010259

UR - https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858719304140?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2213858719304140%3Fshowall%3Dtrue&referrer=https:%2F%2Fpure.aston.ac.uk%2Fadmin%2Feditor%2Fdk%2Fatira%2Fpure%2Fapi%2Fshared%2Fmodel%2Fresearchoutput%2Feditor%2Fcontributiontojournaleditor.xhtml%3Fscheme%3D%26type%3D%26showMigrationIfUnknown%3Dtrue

U2 - 10.1016/S2213-8587(19)30414-0

DO - 10.1016/S2213-8587(19)30414-0

M3 - Letter, comment/opinion or interview

C2 - 31843565

AN - SCOPUS:85078010259

SN - 2213-8587

VL - 8

SP - 97

EP - 99

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

IS - 2

ER -

Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk

UN SDGs

Access to Document

Other files and links

Cite this